Tagged with EU

Brazil Prof. Dr. Luiz Calistro Balestrassi, founder and president of NEUROTEC® – Biomedical Research & Development Company from Itajubá-MG, Brazil, and his daughter Esperança Balestrassi, Neurotec´s executive director, discuss the past, present, and future challenges of this pioneering medical device company that started in 1985. In this interview, Dr. Balestrassi –…

Switzerland Alessandro di Napoli, CEO of Swiss family-owned pharmaceutical group, TRB Chemedica, discusses the company’s focus on the rheumatology, ophthalmology and neurology niches and the importance of ‘Swissness’ within its internationalization process. TRB Chemedica is a family business set up by your father Guido in 1980, now counting 700 employees globally…

Canada Ian Jacobson, CEO of Juno Pharmaceuticals, presents the company’s business model of in-licensing and repurposing generic products. He highlights the successful development of the company’s affiliates in Australia, the UK and South Africa, and his plans to refocus efforts on the Canadian market in the near future, aiming to launch…

Poland Drago Vuina, corporate vice-president of Novo Nordisk Eastern Europe, highlights Poland as the most significant market in the region and the on-going commitment to make innovative treatment options available for patients. Furthermore, he discusses Novo Nordisk’s strong commitment to social responsibility in each country throughout the region and the need…

Canada John London, CEO at Nuvo Pharmaceuticals Inc., explains how he and his partners turned the Canadian company from insolvency into a profitable enterprise with FDA approved products that are being marketed around the world. He further talks opportunities in the topical pain management market and how Nuvo Pharmaceuticals will enhance…

Brazil Luis Eduardo Caroli, CEO of BioZeus, is contributing to the pre-commercial development of Brazilian-born innovations. In this interview he explains how he set up the company and documents the company’s unique model of collaboration between local project managers and highly experienced senior international executives to develop academic science, as well…

Tunisia Hechmi Louzir, general manager of the Institut Pasteur in Tunis (IPT), details the crucial role that the IPT plays in the development of the Tunisian health sector, his wide-ranging responsibilities as general manager, the increasing importance of building new partnerships between the private and public sectors, and the Institute’s ambition…

Austria Philipp Lindinger, managing director of Austromed, the Austrian association for medical devices and in-vitro diagnostics, discusses the organization’s purpose, the impact of European regulation on medical devices on the sector, the importance of a strong notified body system, and the steps required to stimulate future growth within the Austrian medical…

Austria Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of Yondelis®, the company’s flagship product. Furthermore, he provides an overview of the clinical trials the Austrian affiliate is undertaking and…

Canada Dr. Fernand Labrie shares the significant achievements of Endoceutics, in launching its first breakthrough product for post-menopausal vulvar and vaginal atrophy, known as the ‘female Viagra’, the innovations behind the specialty area of ‘intracrinology’ that he discovered, and his perspective on the importance of homegrown innovation for Canada’s development. Having…

Canada Jonathan Ross Goodman, founder and CEO of Knight Therapeutics Inc., discusses the unique backstory behind the founding of the company, coming on the heels of the sale of Paladin Labs Inc., his previous company, for CAD 3.2 billion, the cycling accident that left him brain-damaged but more committed than ever…

Bulgaria Assena Stoimenova, member of the management board of the European Medicines Agency (EMA) and executive director of the Bulgarian Drug Agency (BDA), explains the Agency’s evolution under her tenure as well as her commitment to ensuring that the BDA remains predictable, transparent and fair, being fully focused on safeguarding patients…